Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial
Related Experiment Video
Updated: Dec 26, 2025
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
Published on: December 29, 2021
Daryl Efron1,2,3, Kaitlyn Taylor4, Jonathan M Payne3,5
1Health Services, Murdoch Childrens Research Institute, Parkville, Victoria, Australia daryl.efron@rch.org.au.
Insights
This pilot study explores the feasibility of using cannabidiol (CBD) to manage severe behavioural problems (SBPs) in children with intellectual disability (ID). It aims to inform a larger trial on CBD
Area of Science:
- Pediatric Neurology
- Psychopharmacology
- Clinical Trial Design
Background:
- Severe behavioural problems (SBPs) significantly impact children with intellectual disability (ID).
- Current treatments for SBPs carry high risks of adverse effects.
- Medicinal cannabis, particularly cannabidiol (CBD), shows potential as a safer alternative.
Purpose of the Study:
- To assess the feasibility of a randomized controlled trial (RCT) for CBD in treating SBPs in children with ID.
- To evaluate the acceptability and safety of CBD as an intervention for SBPs.
- To gather data for designing a full-scale efficacy trial.
Main Methods:
- A single-site, double-blind, placebo-controlled pilot study.
- 10 children (aged 8-16 years) with ID and SBPs were randomized (1:1) to receive CBD (20 mg/kg/day) or placebo for 8 weeks.
- Feasibility metrics included recruitment, retention, adherence, and parent questionnaire burden; safety and adverse events were monitored.
Main Results:
- Data collection focused on feasibility and acceptability metrics.
- Safety outcomes and adverse events were systematically recorded.
- Descriptive statistics will be used to analyze feasibility data.
Conclusions:
- This pilot study provides crucial feasibility data for a larger RCT on CBD for SBPs in children with ID.
- Findings will guide the design of a definitive trial to establish CBD's efficacy and safety.
- The study addresses the urgent need for innovative and safe interventions for SBPs in this vulnerable population.
Introduction:
Severe behavioural problems (SBPs) are a common contributor to morbidity and reduced quality of life in children with intellectual disability (ID). Current medication treatment for SBP is associated with a high risk of side effects. Innovative and safe interventions are urgently needed. Anecdotal reports and preliminary research suggest that medicinal cannabis may be effective in managing SBP in children with developmental disabilities. In particular, cannabidiol (CBD) may be a plausible and safe alternative to current medications. Families who are in urgent need of solutions are seeking cannabis for their ID children with SBP. However there is no evidence from randomised controlled trials to support the use of CBD for SBP. This pilot study aims to investigate the feasibility of conducting a randomised placebo-controlled trial of CBD to improve SBP in children with ID.
Methods And Analysis:
This is a single-site, double-blind, parallel-group, randomised, placebo-controlled pilot study of 10 participants comparing 98% CBD oil with placebo in reducing SBP in children aged 8-16 years with ID. Eligible participants will be randomised 1:1 to receive either CBD 20 mg/kg/day or placebo for 8 weeks. Data will be collected regarding the feasibility and acceptability of all study components, including recruitment, drop-out rate, study visit attendance, protocol adherence and the time burden of parent questionnaires. Safety outcomes and adverse events will be recorded. All data will be reported using descriptive statistics. These data will inform the design of a full scale randomised controlled trial to evaluate the efficacy of CBD in this patient group.
Ethics And Dissemination:
This protocol has received ethics approval from the Royal Children's Hospital ethics committee (Human Research Ethics Committee no. 38236). Results will be disseminated through peer-reviewed journals, professional networks, conferences and social media.
Trial Registration Number:
ACTRN12618001852246.
